FTCM
HBIO icon

First Trust Capital Management’s Harvard Bioscience HBIO Stock Holding History

First Trust Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,435
Closed -$135K – 35
2019
Q4 		$135K Buy
+4,435
New +$128K 0.04% 41

Other funds holding HBIO

ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

First Trust Capital Management's HBIO Position: Q1 2020 in Review

First Trust Capital Management sold out of Harvard Bioscience (HBIO) in Q1 2020, closing a stake of 4,435 shares — an estimated $135K sold.

First Trust Capital Management first reported a position in HBIO in Q4 2019 and held it in 1 quarter. The position peaked at $135K in Q4 2019. 64 funds tracked by Wall St. Rank hold HBIO as of Q1 2020.

  • First Trust Capital Management reported no remaining Harvard Bioscience position as of Q1 2020 after selling out during the quarter.
  • First Trust Capital Management sold 4,435 Harvard Bioscience shares in Q1 2020, an estimated $135K.
  • First Trust Capital Management first reported a position in Harvard Bioscience in Q4 2019 and held it in 1 quarter.
  • First Trust Capital Management's Harvard Bioscience position peaked at $135K in Q4 2019.
  • 64 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2020.

Based on First Trust Capital Management's 13F filing for Q1 2020, filed 15 May 2020.